SEC Tracker
Get the app

Altair International PREM

Altair International Q2 FY24: revenue $4.0M; diluted EPS $0.00

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q

Key figures from this report

These are the numbers Altair International reported for Q2 FY24, the quarter ended Sep 30, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$4.0MNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$39KAgainst −$40K in Q2 FY2410-Q income statement, on EDGAR
  3. Diluted EPS$0.00No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$461−94% from $8K in Q2 FY2410-Q balance sheet, on EDGAR
  5. Cash from operations−$33KAgainst −$51K in Q2 FY2410-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Altair International files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. QHSLab USAQ public float $2M, Jun 30, 2025
  2. Vycor Medical VYCO public float $2M, Jun 30, 2025
  3. Profusa PFSA public float $1M, Jun 30, 2025
  4. Semler Scientific SMLR
  5. INVO Fertility IVF public float $2M, Jun 30, 2025